A Comprehensive Prognostic Stratification for Patients with Metastatic Renal Clear Cell Carcinoma
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To develop a reliable prognostic model for patients with metastatic renal cell carcinoma (RCC) based on features readily available in common clinical settings. Patients and Methods: A total of 197 patients with RCC who underwent nephrectomy and immunotherapy from 1995 to 2004 were retrospectively reviewed. Their mean age was 55.1 ±11.8 yrs (24-83yrs) and mean survival time from metastasis was 22.6 ±20.2mos (3-120mos). The impact of 24 clinicopathological features on disease specific survival was investigated. Results: On univariate analysis, constitutional symptoms, sarcomatoid differentiation, tumor necrosis, multiple primary lesions, liver metastasis, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), thrombocytosis, alkaline phosphatase, hematocrit, T stage, N stage, and nuclear grade had significant influence on survival (p<0.05). Multivariate analysis revealed the following features associated with survival: sarcomatoid differentiation [hazard ratio (HR)=2.99, p<0.001], liver metastasis (HR=2.09, p= 0.002), ECOG-PS (HR=1.95, p= 0.005), N stage (HR=1.94, p=0.002), and number of metastatic sites (HR=1.76, p=0.003). An individual prognostic score was defined as the sum of the weight of these features. According to prognostic scores, patients could be subdivided into 3 groups: low risk (score 0), intermediate risk (score 1 or 2), and high risk (score ≥3). Conclusion: A comprehensive prognostic stratification model was developed to predict survival and stratify patients for prospective clinical trials.
Abstract
Purpose: To develop a reliable prognostic model for patients with metastatic renal cell carcinoma (RCC) based on features readily available in common clinical settings. Patients and Methods: A total of 197 patients with RCC who underwent nephrectomy and immunotherapy from 1995 to 2004 were retrospectively reviewed. Their mean age was 55.1 ±11.8 yrs (24-83yrs) and mean survival time from metastasis was 22.6 ±20.2mos (3-120mos). The impact of 24 clinicopathological features on disease specific survival was investigated. Results: On univariate analysis, constitutional symptoms, sarcomatoid differentiation, tumor necrosis, multiple primary lesions, liver metastasis, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), thrombocytosis, alkaline phosphatase, hematocrit, T stage, N stage, and nuclear grade had significant influence on survival (p<0.05). Multivariate analysis revealed the following features associated with survival: sarcomatoid differentiation [hazard ratio (HR)=2.99, p<0.001], liver metastasis (HR=2.09, p= 0.002), ECOG-PS (HR=1.95, p= 0.005), N stage (HR=1.94, p=0.002), and number of metastatic sites (HR=1.76, p=0.003). An individual prognostic score was defined as the sum of the weight of these features. According to prognostic scores, patients could be subdivided into 3 groups: low risk (score 0), intermediate risk (score 1 or 2), and high risk (score ≥3). Conclusion: A comprehensive prognostic stratification model was developed to predict survival and stratify patients for prospective clinical trials.
참고문헌 (22)
- Motzer RJ, "Renal-cell carcinoma", N Engl J Med, 335, pp.865~875 (1996)
- Pantuck AJ, "The changing natural history of renal cell carcinoma", J Urol, 166, pp.1611~1623 (2001)
- Flanigan RC, "Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer", Engl J Med, 345, pp.1655~1659 (2001)
- Mickisch GH, "European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial", Lancet, 358, pp.966~970 (2001)
- Bellmunt J, "Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents", BJU Int, 99, pp.274~280 (2007)
- Atzpodien J, "DGCIN- German Cooperative Renal Carcinoma Chemo- Immunotherap Trial Group. Metastatic renal carcinoma comprehensive prognostic system", Br J Cancer, 88, pp.348~353 (2003)
- Leibovich BC, "A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials", J Urol, 174, pp.1759~1763 (2005)
- Leibovich BC, "Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials", Cancer, 98, pp.2566~2575 (2003)
- Motzer RJ, "Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma", J Clin Oncol, 20, pp.289~296 (2002)
- Motzer RJ, "Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma", J Clin Oncol, 17, pp.2530~2540 (1999)
- Zisman A, "Improved prognostication of renal cell carcinoma using an integrated staging system", J Clin Oncol, 19, pp.1649~1657 (2001)
- Zisman A, "Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma", J Clin Oncol, 20, pp.4559~4566 (2002)
- Frank I, "An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score", J Urol, 168, pp.2395~2400 (2002)
- de Forges A, "Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis", Semin Surg Oncol, 4, pp.149~154 (1988)
- Lopez Hänninen E, "Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients", J Urol, 155, pp.19~25 (1996)
- Jones M, "The impact of interleukin-2 on survival in renal cancer: a multivariate analysis", Cancer Biother, 8, pp.275~288 (1993)
- Palmer PA, "Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2", Ann Oncol, 3, pp.475~480 (1992)
- Elson PJ, "Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma", Cancer Res, 48, pp.7310~7313 (1988)
- Fosså SD, "Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha", Eur J Cancer, 30A, pp.1310~1314 (1994)
- Amin MB, "Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases", Am J Surg Pathol, 26, pp.281~291 (2002)
- Berndt SI, "Disparities in treatment and outcome for renal cell cancer among older black and white patients", J Clin Oncol, 25, pp.3589~3595 (2007)
- Tripathi RT, "Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma", Urology, 68, pp.696~301 (2006)